Healthspan Capital

Healthspan Capital is a venture capital firm dedicated to advancing longevity biotechnology and regenerative medicine. The firm focuses on investing in companies that aim to significantly extend human lifespan by targeting the fundamental drivers of aging. Their portfolio includes startups specializing in DNA repair, regenerative medicine, and other groundbreaking areas that promise to revolutionize approaches to aging and healthcare.

The firm's investment strategy encompasses a wide range of stages, from seed to late-stage funding, including Series A, Series B, growth, and pre-IPO rounds. Geographically, Healthspan Capital has a diverse focus, with investments in the United States, United Kingdom, Switzerland, Germany, Denmark, and Israel. The industries they target include healthcare, biotechnology, regenerative medicine, longevity, and life sciences.

Healthspan Capital's track record includes over 30 deals in just two years, making it one of the most active investors in the longevity space. Their approach combines open-source AI screening with crowd-reviewed evidence, ensuring transparency and community involvement in the investment process. This methodology allows backers to choose projects or diversify automatically, driving tangible impact through radical transparency.